Título:	Avaliação in vitro da inibição da atividade de proteínas RAS por derivados de quinolonas no modelo câncer pancreático humano
Autor(es):	Redorat, Felipe Silva
Orientador(es):	Corrêa, José Raimundo
Assunto:	Câncer de pâncreas Pâncreas - câncer Proteínas - análise Quimioterapia Quinolonas
Data de publicação:	31-Jul-2017
Data de defesa:	31-Mar-2017
Referência:	REDORAT, Felipe Silva. Avaliação in vitro da inibição da atividade de proteínas RAS por derivados de quinolonas no modelo câncer pancreático humano. 2017. vi, 58 f., il. Dissertação (Mestrado em Biologia Molecular)—Universidade de Brasília, Brasília, 2017.
Abstract:	In the Brazil, pancreatic cancer represents 2% of all cancer types. Accounting for 4% of all deaths from this disease. Its treatment is rarely restricted to the surgical removal of the tumor due to the high aggressiveness of this disease. For most cases the alternative therapy is surgery and/or chemotherapy associated or not with radiotherapy. Pancreatic cancer is a silent disease with a generally late diagnosis, which makes treatment difficult because of metastases presence. This factor also contributes decisively to a poor prognosis and a very short life after diagnosis, ranging from six to eighteen months for many the cases. The first choice drugs that are used in chemotherapy of this type of cancer, Gemcitabine and the 5-fluororacil (5-FU), act interfering with the cellular capacity to synthesize its DNA, thus inhibiting the mitosis and inducing the cell death by apoptosis. Because the mechanisms of action of these drugs cause high toxicity to all cells, the treatment of pancreatic cancer is associated with several severe adverse effects such as pancytopenia. Despite therapeutic advances in the treatment of cancer, pancreatic cancer persists as the major challenge, urgently requiring central therapeutic alternatives and adjuvants, which are efficient in eliminating tumor and tumor cells with less toxicity to normal cells. Based on the above, our group went on to evaluate the RAS protein (KRAS), changed in more than 40% of cases of pancreatic cancers. Next, our group synthesized nine quinolone derivatives with computational potential of indirectly interfering with the activity of RAS proteins. Thus, the objective of this work was to carry out the proof of concept on the properties of the quinolones derivatives to reduce or cancel the abnormal activity of KRAS, in the expectation that this potential inhibition could contribute to the reduction of the rate of cell proliferation, reduction of migration Cell and induction of apoptosis in these tumor cells. Although the agents evaluated here have not presented promising results for their direct use, our results open a wide horizon for the synthesis of other series of quinolone derivatives that with high potential of use as effective drugs in the treatment of pancreatic cancer.
Unidade Acadêmica:	Instituto de Ciências Biológicas (IB) Departamento de Biologia Celular (IB CEL)
Informações adicionais:	Dissertação (mestrado)—Universidade de Brasília, Departamento de Biologia Celular, Programa de Pós-Graduação em Biologia Molecular, 2017.
Programa de pós-graduação:	Programa de Pós-Graduação em Biologia Molecular
Licença:	A concessão da licença deste item refere-se ao termo de autorização impresso assinado pelo autor com as seguintes condições: Na qualidade de titular dos direitos de autor da publicação, autorizo a Universidade de Brasília e o IBICT a disponibilizar por meio dos sites www.bce.unb.br, www.ibict.br, http://hercules.vtls.com/cgi-bin/ndltd/chameleon?lng=pt&skin=ndltd sem ressarcimento dos direitos autorais, de acordo com a Lei nº 9610/98, o texto integral da obra disponibilizada, conforme permissões assinaladas, para fins de leitura, impressão e/ou download, a título de divulgação da produção científica brasileira, a partir desta data.
DOI:	http://dx.doi.org/10.26512/2017.03.D.23968
Aparece nas coleções:	Teses, dissertações e produtos pós-doutorado

Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.